Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
Katharina C. Kaehler(Christian-Albrechts-Universität zu Kiel), Dirk Schadendorf(National Center for Tumor Diseases), Bastian Schilling(Goethe University Frankfurt), Axel Hauschild(University Hospital Schleswig-Holstein), Sarah Piel(Düsseldorf University Hospital), Elisabeth Livingstone(German Cancer Research Center)
Cited by 170
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k